Search results
Showing results for
The Nuffield Department of Medicine (NDM) at the University of Oxford has a global reach and significant breadth in terms of capabilities and capacity.
Charles Sande: Paediatric infection and immunity
Charles Sande investigates why some children in sub‑Saharan Africa survive infections while others do not. Using proteomics, transcriptomics, metagenomics and clinical data, his work identified immune differences linked to mortality. A recent multi-country study highlighted IL10 as a key marker of high-risk children, supporting more targeted care and personalised interventions.
Wirichada Pan ngum: Modeling for maximum impact on health research
Wirichada Pan ngum leads a modelling group using statistical and mathematical approaches to address regional health challenges. Her work on hepatitis C informed Thailand’s treatment and screening policies. Current priorities include integrating AI into modelling and addressing climate change and mental health. Her team also focuses on local capacity building for sustainable impact.
Anthony Etyang: Unmasking hypertension - the silent killer
Anthony studies hypertension in Kenya and The Gambia, focusing on improving diagnosis, treatment, and blood pressure control. His research addresses low awareness and treatment gaps, aiming to prevent severe outcomes like stroke and heart failure. With over 25% of adults affected, his work targets a major cause of premature death in Africa.
Sonia Lewycka: One Health interventions to combat antimicrobial resistance
Antimicrobial resistance can be viewed through a One Health lens across humans, animals and the environment. Focussing on primary care, tests offered at point-of-care in Vietnam to curb antibiotic overuse yielded promising but nuanced results. The Just Transition initiative, examining justice implications of AMR policies globally, aims to align efforts with climate change mitigations for mutual benefits.
Mike English: Hospitals and Health for All?
Health Systems Collaborative focuses on improving healthcare delivery for low-income populations in Africa, especially in hospitals in rural areas. The AFRHiCARE project, a collaboration with clinicians, social scientists, and economists in Uganda, Kenya, South Africa and Oxford, examines how hospitals can effectively utilise technologies and innovations. We aim to optimise hospital operations to deliver high-quality care, ensuring essential services for patients in resource-poor settings across Africa.
Raph Hamers: Infectious diseases research in Indonesia
Infectious diseases research at OUCRU Indonesia addresses prevention, diagnosis and management, focusing on tuberculosis, HIV, COVID-19 and antimicrobial resistance. Participation in the RECOVERY trial contributed to the identification of four treatments for severe COVID-19. Challenges include the need of more research expertise and translating findings into policy. Our goal is to reduce disease burdens through technical and implementation innovations.
Sophie Yacoub: Dengue research in Vietnam
Dengue is a global health concern exacerbated by urbanisation and climate change. OUCRU research themes include improving patient monitoring with wearable devices and clinical decision support systems, conducting clinical trials for therapeutics, assessing climate change's impact, and studying immune responses in high-risk groups. Our goal is to enhance early prediction and treatment strategies to improve patient care and health system efficiency.
Abhilasha Karkey: Infectious diseases in Nepal
The primary goal of OUCRU-Nepal is to improve public health in Nepal and South Asia, with focus on typhoid, antimicrobial resistance, and dengue increase linked with climate change. Over the recent years, the TCV typhoid vaccine trial emphasized the importance of regional collaboration and working with policymakers. OUCRU-Nepal has built strong hospital and community relationships, boosting global visibility and collaborations.
Paul Turner: Improving data for infection management
The ACORN project gathers clinical, microbiology, and antibiotic use data from nine countries in Asia and Africa to understand the burden and impact of antibiotic resistance on patient treatment and outcomes. It aims to improve direct patient care, generate treatment guidelines, and inform interventions to combat antibiotic resistance globally, ensuring better antibiotics for all.
Claire Chewapreecha: Melioidosis genomics
Genetic investigations into melioidosis, profiling both bacteria and patients, help understand disease acquisition and outcomes. Furthermore, identifying prevalent harmful bacterial genes supports vaccine development, and the development of CRISPR-Cas-based tests responds to an urgent need for rapid diagnosis that can reduce the detection time to under three hours with higher sensitivity. Applications developed in resource-limited settings show improved global applicability and impact on patients’ outcomes.
Mavuto Mukaka: Statistics for medical studies
Medical statisticians help design studies, perform data cleaning and analysis, and interpret findings. Many methods are available, and statisticians help identify and make recommendations. Poorly designed and interpreted studies may lead to wrong conclusions, and statisticians help ensure better findings that can be translated into medical practice and policy change.
Jay Berkley: Infections, nutrition and survival
Child mortality from infectious diseases in the tropics has decreased, but a high fatality rate in hospital and post-discharge remains for vulnerable groups such as newborns and malnourished children. The CHAIN Networks looks at preventable causes of death across 9 sites in Africa and South Asia, conducting clinical trials to improve treatments and guidelines, to improve outcomes.
David Stuart: Structural biology and vaccines
The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.
Kay Grunewald: Structural cell biology of virus infection
Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.
Paul Newton: Poor quality medicines
Poor quality medicines are a serious threat to our health. Falsified medicines and substandards medicines are a problem for all countries, but particularly for low and middle income countries where we see, for example, a large epidemic of fake anti-malarial drugs. Globally, better medicine regulatory authorities will help improve the quality of our medicines.
Jens Rittscher: Biological imaging
Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.
Sebastian Nijman: Pharmacogenomics
In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.
Ian Pavord: Asthma
Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.